Evidence map›Paper›PMID 24135786›Full record

ArticleEpigenetics2013

Expression and epigenetic regulation of angiogenesis-related factors during dormancy and recurrent growth of ovarian carcinoma.

Tianjiao Lyu, Nan Jia, Jieyu Wang, Xiaohui Yan, Yinhua Yu, Zhen Lu, Robert C Bast, Keqin Hua, Weiwei Feng

Open access · hybridAbstract read
In one paragraph

Article in Epigenetics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 63 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Angioregulatory microRNAs in breast cancerJournal of advanced research · 2022
    Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Autophagy and Cancer Dormancy.Frontiers in oncology · 2021
    Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Tianjiao LyuDepartment of Gynecology; Shanghai Key Laboratory of Female Reproductive Endocrine-Related Diseases, Obstetrics and Gynecology Hospital; Fudan University; Shanghai, PR China; Shanghai Key Laboratory of Female Reproductive Endocrine-Related Diseases, Obstetrics and Gynecology Hospital; Fudan University; Shanghai, PR China.
Nan JiaDepartment of Gynecology; Shanghai Key Laboratory of Female Reproductive Endocrine-Related Diseases, Obstetrics and Gynecology Hospital; Fudan University; Shanghai, PR China; Shanghai Key Laboratory of Female Reproductive Endocrine-Related Diseases, Obstetrics and Gynecology Hospital; Fudan University; Shanghai, PR China.
Jieyu WangDepartment of Gynecology; Shanghai Key Laboratory of Female Reproductive Endocrine-Related Diseases, Obstetrics and Gynecology Hospital; Fudan University; Shanghai, PR China; Shanghai Key Laboratory of Female Reproductive Endocrine-Related Diseases, Obstetrics and Gynecology Hospital; Fudan University; Shanghai, PR China.
Xiaohui YanDepartment of Gynecology; Shanghai Key Laboratory of Female Reproductive Endocrine-Related Diseases, Obstetrics and Gynecology Hospital; Fudan University; Shanghai, PR China; Shanghai Key Laboratory of Female Reproductive Endocrine-Related Diseases, Obstetrics and Gynecology Hospital; Fudan University; Shanghai, PR China.
Yinhua YuDepartment of Gynecology; Shanghai Key Laboratory of Female Reproductive Endocrine-Related Diseases, Obstetrics and Gynecology Hospital; Fudan University; Shanghai, PR China; Shanghai Key Laboratory of Female Reproductive Endocrine-Related Diseases, Obstetrics and Gynecology Hospital; Fudan University; Shanghai, PR China; Department of Experimental Therapeutics; University of Texas, M.D. Anderson Cancer Center; Houston, TX USA.
Zhen LuDepartment of Experimental Therapeutics; University of Texas, M.D. Anderson Cancer Center; Houston, TX USA.
Robert C BastDepartment of Experimental Therapeutics; University of Texas, M.D. Anderson Cancer Center; Houston, TX USA.
Keqin HuaDepartment of Gynecology; Shanghai Key Laboratory of Female Reproductive Endocrine-Related Diseases, Obstetrics and Gynecology Hospital; Fudan University; Shanghai, PR China; Shanghai Key Laboratory of Female Reproductive Endocrine-Related Diseases, Obstetrics and Gynecology Hospital; Fudan University; Shanghai, PR China.
Weiwei FengDepartment of Gynecology; Shanghai Key Laboratory of Female Reproductive Endocrine-Related Diseases, Obstetrics and Gynecology Hospital; Fudan University; Shanghai, PR China; Shanghai Key Laboratory of Female Reproductive Endocrine-Related Diseases, Obstetrics and Gynecology Hospital; Fudan University; Shanghai, PR China.
Fudan University · CNObstetrics and Gynecology Hospital of Fudan University · CNThe University of Texas MD Anderson Cancer Center · US

Funding

UNIVERSITY OF TEXAS MD ANDERSON SPORE IN OVARIAN CANCERP50CA083639 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BAST, ROBERT C · 1999 to 2015
$33.0M
Supplement to CA135354 "ARHI (DIRAS3) in Autophagy and Dormancy of Ovarian Cancer"R01CA135354 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BAST, ROBERT C · 2009 to 2019
$3.5M
NCI NIH HHS P50 CA083639NCI NIH HHS P50 CA83639NCI NIH HHS R01 CA135354NCI NIH HHS R01 CA135354-01
6 · The paper itself

Abstract

The initiation of angiogenesis can mark the transition from tumor dormancy to active growth and recurrence. Mechanisms that regulate recurrence in human cancers are poorly understood, in part because of the absence of relevant models. The induction of ARHI (DIRAS3) induces dormancy and autophagy in human ovarian cancer xenografts but produces autophagic cell death in culture. The addition of VEGF to cultures maintains the viability of dormant autophagic cancer cells, thereby permitting active growth when ARHI is downregulated, which mimics the "recurrence" of growth in xenografts. Two inducible ovarian cancer cell lines, SKOv3-ARHI and Hey-ARHI, were used. The expression level of angiogenesis factors was evaluated by real-time PCR, immunohistochemistry, immunocytochemistry and western blot; their epigenetic regulation was measured by bisulfite sequencing and chromatin immunoprecipitation. Six of the 15 angiogenesis factors were upregulated in dormant cancer cells (tissue inhibitor of metalloproteinases-3, TIMP3; thrombospondin-1, TSP1; angiopoietin-1; angiopoietin-2; angiopoietin-4; E-cadherin, CDH1). We found that TIMP3 and CDH1 expression was regulated epigenetically and was related inversely to the DNA methylation of their promoters in cell cultures and in xenografts. Increased H3K9 acetylation was associated with higher TIMP3 expression in dormant SKOv3-ARHI cells, while decreased H3K27me3 resulted in the upregulation of TIMP3 in dormant Hey-ARHI cells. Elevated CDH1 expression during dormancy was associated with an increase in both H3K4me3 and H3K9Ac in two cell lines. CpG demethylating agents and/or histone deacetylase inhibitors inhibited the re-growth of dormant cancer cells, which was associated with the re-expression of anti-angiogenic genes. The expression of the anti-angiogenic genes TIMP3 and CDH1 is elevated during dormancy and is reduced during the transition to active growth by changes in DNA methylation and histone modification.

Indexed as

Epigenesis, GeneticAcetylationAnimalsAutophagyCarcinoma, Ovarian EpithelialCell Line, TumorCell ProliferationDNA MethylationFemaleGene Expression Regulation, NeoplasticHeterograftsHistonesHumansMiceMice, NudeNeoplasm Recurrence, LocalHistonesangiogenesisdormancyhistone modificationmethylationovarian cancerrecurrence

Identifiers

PMID24135786
PMCPMC3933493
OpenAlexW2000285730

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.